ArticleJCO clinical cancer informatics2019
Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery.
Article in JCO clinical cancer informatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Review
- Mathematical modeling of the synergetic effect between radiotherapy and immunotherapy.Mathematical biosciences and engineering : MBE · 2025Article
- Mathematical modeling in radiotherapy for cancer: a comprehensive narrative review.Radiation oncology (London, England) · 2025Review
- The impact of single and multiple occurrences, as well as the sequence of occurrences, of primary gastrointestinal cancer on overall survival: a comprehensive analysis based on the surveillance, epidemiology, and end results database in the United States from 2016 to 2019.Archives of public health = Archives belges de sante publique · 2024Article
- Spatially fractionated GRID radiation potentiates immune-mediated tumor control.Radiation oncology (London, England) · 2024Article
- Proton Beam Therapy in the Oligometastatic/Oligorecurrent Setting: Is There a Role? A Literature Review.Cancers · 2023Review
- Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system.Neoplasia (New York, N.Y.) · 2022Review
- Optimizing the future: how mathematical models inform treatment schedules for cancer.Trends in cancer · 2022Review
- Dynamics of an Antitumour Model with Pulsed Radioimmunotherapy.Computational and mathematical methods in medicine · 2022Article
- Forecasting Individual Patient Response to Radiation Therapy in Head and Neck Cancer With a Dynamic Carrying Capacity Model.International journal of radiation oncology, biology, physics · 2021Article
- A tumor-immune interaction model for hepatocellular carcinoma based on measured lymphocyte counts in patients undergoing radiotherapy.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020Article
- Article
- Modeling the effect of intratumoral heterogeneity of radiosensitivity on tumor response over the course of fractionated radiation therapy.Radiation oncology (London, England) · 2019Article
- Introduction to Mathematical Oncology.JCO clinical cancer informatics · 2019Article
- Review of Current Accepted Practices in Identification of the Breast Lumpectomy Tumor Bed.Advances in radiation oncologyReview
- The Intersection of Regional Anesthesia and Cancer Progression: A Theoretical Framework.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeEarly-stage cancers are routinely treated with surgery followed by radiotherapy (SR). Radiotherapy before surgery (RS) has been widely ignored for some cancers. We evaluate overall survival (OS) and disease-free survival (DFS) with SR and RS for different cancer types and simulate the plausibility of RS- and SR-induced antitumor immunity contributing to outcomes. MATERIALS AND
methodsWe analyzed a SEER data set of early-stage cancers treated with SR or RS. OS and DFS were calculated for cancers with sufficient numbers for statistical power (cancers of lung and bronchus, esophagus, rectum, cervix uteri, corpus uteri, and breast). We simulated the immunologic consequences of SR, RS, and radiotherapy alone in a mathematical model of tumor-immune interactions.
resultsRS improved OS for cancers with low 20-year survival rates (lung: hazard ratio [HR], 0.88; P = .046) and improved DFS for cancers with higher survival (breast: HR = 0.64; P < .001). For rectal cancer, with intermediate 20-year survival, RS improved both OS (HR = 0.89; P = .006) and DFS (HR = 0.86; P = .04). Model simulations suggested that RS could increase OS by eliminating cancer for a broader range of model parameters and radiotherapy-induced antitumor immunity compared with SR for selected parameter combinations. This could create an immune memory that may explain increased DFS after RS for certain cancers.
conclusionStudy results suggest plausibility that radiation to the bulk of the tumor could induce a more robust immune response and better harness the synergy of radiotherapy and antitumor immunity than postsurgical radiation to the tumor bed. This exploratory study provides motivation for prospective evaluation of immune activation of RS versus SR in controlled clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.